BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29362816)

  • 1. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
    Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
    Zaloum A; Falet JR; Elkrief A; Chalk C
    Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
    [No Abstract]   [Full Text] [Related]  

  • 4. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
    Sawada H; Kanehisa F; Katoh N; Asai J
    J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
    [No Abstract]   [Full Text] [Related]  

  • 5. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
    Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
    Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
    Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
    Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
    Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute intraventricular conduction disorder due to combination therapy with dabrafenib and trametinib for metastatic melanoma: Case report.
    Yamamura K; Matsushita S; Aoki M; Kusumoto K
    J Dermatol; 2018 May; 45(5):e120-e121. PubMed ID: 29178523
    [No Abstract]   [Full Text] [Related]  

  • 10. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.
    Stefanou MI; Gepfner-Tuma I; Brendle C; Kowarik M; Meiwes A; Eigentler T; Müller A; Garbe C; Ziemann U; Tabatabai G; Forschner A
    J Dtsch Dermatol Ges; 2020 Feb; 18(2):136-139. PubMed ID: 31814289
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib.
    Winkler JK; Buder-Bakhaya K; Ellert E; Herpel E; Martens UM; Enk A; Hassel JC
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e31-e32. PubMed ID: 28695986
    [No Abstract]   [Full Text] [Related]  

  • 13. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
    Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
    [No Abstract]   [Full Text] [Related]  

  • 14. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
    Lacroix JP; Wang B
    J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
    Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.
    Flaherty DC; Hoffner BW; Lau BJ; Hamid O; Faries MB
    J Surg Oncol; 2015 Dec; 112(8):844-5. PubMed ID: 26503563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.